Nature Medicine
11, 567 - 571 (2005)
Published online: 10 April 2005; | doi:10.1038/nm1227
Deletion of Gab1 in the liver leads to enhanced glucose tolerance and improved hepatic insulin actionEmilie A Bard-Chapeau1, Andrea L Hevener2, Shinong Long1, Eric E Zhang1, 3, Jerrold M Olefsky2
& Gen-Sheng Feng1, 31
Signal Transduction Program, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, California 92037, USA. 2
Department of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA. 3
Molecular Pathology Graduate Program, Department of Pathology, University of California San Diego, 9500 Gilman Drive, La Jolla, California 92093, USA.
Correspondence should be addressed to Gen-Sheng Feng gfeng@burnham.orgInsulin receptor substrate-1 (IRS-1) and IRS-2 are known to transduce and amplify signals emanating from the insulin receptor1,
2,
3. Here we show that Grb2-associated binder 1 (Gab1), despite its structural similarity to IRS proteins4, is a negative modulator of hepatic insulin action. Liver-specific Gab1 knockout (LGKO) mice showed enhanced hepatic insulin sensitivity with reduced glycemia and improved glucose tolerance. In LGKO liver, basal and insulin-stimulated tyrosine phosphorylation of IRS-1 and IRS-2 was elevated, accompanied by enhanced Akt/PKB activation. Conversely, Erk activation by insulin was suppressed in LGKO liver, leading to defective IRS-1 Ser612 phosphorylation. Thus, Gab1 acts to attenuate, through promotion of the Erk pathway, insulin-elicited signals flowing through IRS and Akt proteins, which represents a novel balancing mechanism for control of insulin signal strength in the liver.
MORE ARTICLES LIKE THIS These links to content published by NPG are automatically generated.
|
